UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Targeted oncology, 2016-06, Vol.11 (3), p.401-415

2016

Volltextzugriff (PDF)

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Annals of oncology, 2010-01, Vol.21 (1), p.109-113

2010

Volltextzugriff (PDF)

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

Annals of oncology, 2012-05, Vol.23 (5), p.1307-1313

2012

Volltextzugriff (PDF)

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

British journal of cancer, 2010-06, Vol.103 (1), p.12-17

2010

Volltextzugriff (PDF)

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Annals of oncology, 2009-01, Vol.20 (1), p.27-33

2009

Volltextzugriff (PDF)

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1241-1249

2012

Volltextzugriff (PDF)

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Annals of oncology, 2016-06, Vol.27 (6), p.1013-1019

2016

Volltextzugriff (PDF)

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

British journal of cancer, 2010-07, Vol.103 (3), p.332-339

2010

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Annals of oncology, 2012-08, Vol.23 (8), p.1968-1973

2012

Volltextzugriff (PDF)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

British journal of cancer, 2012-11, Vol.107 (11), p.1797-1800

2012

Volltextzugriff (PDF)

Hyperglycemia and Phosphatidylinositol 3‐Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

The oncologist (Dayton, Ohio), 2016-07, Vol.21 (7), p.855-860

2016

Volltextzugriff (PDF)

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Annals of oncology, 2020-05, Vol.31 (5), p.626-633

2020

Volltextzugriff (PDF)

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

British journal of cancer, 2006-10, Vol.95 (7), p.767-774

2006

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Cancer chemotherapy and pharmacology, 2011-06, Vol.67 (6), p.1273-1279

2011

Volltextzugriff (PDF)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

British journal of cancer, 2008-03, Vol.98 (5), p.894-899

2008

Volltextzugriff (PDF)

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

European journal of cancer (1990), 2015-09, Vol.51, p.S67-S67

2015

Volltextzugriff (PDF)

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Annals of oncology, 2013-05, Vol.24 (5), p.1416-1418

2013

Volltextzugriff (PDF)

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

British journal of cancer, 2015-12, Vol.113 (11), p.1541-1547

2015

Volltextzugriff (PDF)

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

Journal of neuro-oncology, 2018-08, Vol.139 (1), p.107-116

2018

Volltextzugriff (PDF)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Oncology, 2012-08, Vol.83 (4), p.177-182

2012

Volltextzugriff (PDF)

Phase I trial outcomes in older patients with advanced solid tumours

British journal of cancer, 2016-02, Vol.114 (3), p.262-268

2016

Volltextzugriff (PDF)

Adjuvant therapy of malignant melanoma

Critical reviews in oncology/hematology, 2002-10, Vol.44 (1), p.81-102

2002

Volltextzugriff (PDF)

Gender and survival in malignant tumours

Cancer treatment reviews, 2001-08, Vol.27 (4), p.201-209

2001

Volltextzugriff (PDF)

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials

European journal of cancer (1990), 2011, Vol.47, p.S154-S154

2011

Volltextzugriff (PDF)

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Annals of oncology, 2006-08, Vol.17 (8), p.1313-1319

2006

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Englisch
(108)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(39)
Oncology
(37)
Middle Aged
(30)
Aged
(29)
Male
(28)
Adult
(25)
Female
(25)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Neoplasms - Drug Therapy
(17)
Tumors
(17)
Antineoplastic Agents
(12)
Cancer Research
(12)
Pharmacology. Drug Treatments
(12)
Antineoplastic Agents - Adverse Effects
(11)
Aged, 80 And Over
(10)
Biomedicine
(10)
Retrospective Studies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and or paclitaxel in patients with solid tumours

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents

Hyperglycemia and Phosphatidylinositol 3‐Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH)

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials

Phase I trial outcomes in older patients with advanced solid tumours

Adjuvant therapy of malignant melanoma

Gender and survival in malignant tumours

1232 POSTER Creatinine Clearance (CrCI) as a Predictive Marker for the Risk of Toxicity From Molecularly Targeted Agents (MTA) in Phase I Trials

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Suchergebnisse filtern